ANL
Adlai Nortye Ltd.
NASDAQ · Healthcare · Biotechnology · KY
$15.01
+1.76%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 19.7M | 5.0M | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | 19.7M | 5.0M | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 32.2M | 32.8M | 44.9M | 58.2M | 54.5M |
| SG&A Expense | 10.0M | 7.8M | 9.4M | 14.8M | 12.4M |
| General & Admin Expense | 10.0M | 7.8M | 9.4M | 14.8M | 12.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (256.0K) | 80.0K | (1.4M) | (425.0K) | 350.0K |
| Total Operating Expenses | 42.0M | 40.7M | 52.9M | 72.6M | 67.3M |
| Cost and Expenses | 42.0M | 40.7M | 52.9M | 72.6M | 67.3M |
| Operating Income (EBIT) | (22.3M) | (35.7M) | (52.9M) | (72.6M) | (67.3M) |
| Non-Operating | |||||
| Interest Income | — | — | — | 62.0K | 550.0K |
| Interest Expense | 1.3M | 1.5M | 1.9M | 791.0K | 433.0K |
| Net Interest Income | (1.3M) | (1.5M) | (1.9M) | (729.0K) | 117.0K |
| Other Non-Op Income/Expense | (236.0K) | 170.0K | 1.1M | (36.7M) | 8.5M |
| Non-Operating Income (excl Interest) | — | (1.7M) | (3.0M) | 35.9M | (8.9M) |
| EBT (Pre-Tax Income) | (22.5M) | (35.5M) | (51.9M) | (109.2M) | (58.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (22.5M) | (35.5M) | (51.9M) | (109.2M) | (58.8M) |
| Earnings from Cont. Ops | (22.5M) | (35.5M) | (51.9M) | (109.2M) | (58.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (22.5M) | (35.5M) | (51.9M) | (109.2M) | (58.8M) |
| Per Share | |||||
| Basic EPS | ($1.96) | ($3.33) | ($4.89) | ($15.42) | ($4.77) |
| Diluted EPS | ($1.96) | ($3.33) | ($4.89) | ($15.42) | ($4.77) |
| Revenue Per Share | $1.24 | $0.47 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 15.9M | 10.7M | 10.6M | 6.8M | 12.3M |
| Diluted Shares Outstanding | 15.9M | 10.7M | 10.6M | 6.8M | 12.3M |
| Profitability Metrics | |||||
| EBITDA | (21.5M) | (32.6M) | (48.1M) | (106.2M) | (56.3M) |
| D&A | 823.3K | 1.4M | 1.9M | 2.2M | 2.0M |
| EBIT | (22.3M) | (34.0M) | (49.9M) | (108.4M) | (58.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026